Aquestive Therapeutics Stock News

Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also drew strength from some

Wall Street brokerages expect Aquestive Therapeutics, Inc. (NASDAQ:AQST) to announce ($0.37) earnings per share for the current quarter, Zacks reports. Two analysts have made estimates for Aquestive Therapeutics earnings, with estimates ranging from ($0.42) to ($0.32). Aquestive Therapeutics posted earnings of ($0.60) per share during the same quarter last year, which would suggest a positive []

Aquestive Therapeutics Inc. (NASDAQ:AQST) shares, rose in value on Thursday, 12/16/21, with the stock price up by 4.57% to the previous day’s close as strong demand from buyers drove the stock to $5.49. Actively observing the price movement in the last trading, the stock closed the session at $5.25, falling within a range of $5.32 … Read This First Before You Buy Aquestive Therapeutics Inc. (NASDAQ: AQST) Stock Read More »

WARREN, N.J., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that

WARREN, N.J., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients unmet needs and solve therapeutic problems, today announced that NASDAQ has added the company to the NASDAQ Biotechnology Index® (Nasdaq: NBI) effective December 20, 2021.

Aquestive Therapeutics Inc. (NASDAQ:AQST) price on Friday, December 10, fall -3.47% below its previous days close as a downside momentum from buyers pushed the stocks value to $5.01. A look at the stocks price movement, the close in the last trading session was $5.19, moving within a range at $4.98 and $5.2942. The beta value What Can Aquestive Therapeutics Inc. (NASDAQ: AQST) Expect In 2021? Read More »

State Street Corp lessened its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 78.4% during the second quarter, Holdings Channel.com reports. The firm owned 69,877 shares of the companys stock after selling 253,766 shares during the quarter. State Street Corps holdings in Aquestive Therapeutics were worth $277,000 at the end of the most recent quarter. A []

In the last trading session, 1.14 million Aquestive Therapeutics Inc. (NASDAQ:AQST) shares changed hands as the companys beta touched 3.47. With the companys per share price at $4.84 changed hands at -$0.54 or -10.04% during last session, the market valuation stood at $216.11M. AQSTs last price was a discount, traded about -66.53% off its 52-week Aquestive Therapeutics Inc. (NASDAQ: AQST) Stock Forecast For 2021: Bullish Signs Point To $28.00 Per Share Read More »

A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for the year-to-date peri

Aquestive Therapeutics is moving closer to Libervant's PDUFA date in December. If approved, Aquestive will finish 2021 on a bullish note that can be sustained into 2022. Aquestive has fought through C

Squarepoint Ops LLC acquired a new position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 19,824 shares of the companys stock, valued at approximately $79,000. Squarepoint Ops LLC owned approximately 0.05% of Aquestive []

During the last session, Aquestive Therapeutics Inc. (NASDAQ:AQST)s traded shares were 0.6 million, with the beta value of the company hitting 3.51. At the end of the trading day, the stocks price was $6.24, reflecting an intraday gain of 4.17% or $0.25. The 52-week high for the AQST share is $8.06, that puts it down Aquestive Therapeutics Inc. (NASDAQ: AQST) Stock Jumped 26.06% Over A Month Are There Any Chances Of Growth? Read More »

Brokerages expect that Aquestive Therapeutics, Inc. (NASDAQ:AQST) will report earnings per share (EPS) of ($0.37) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Aquestive Therapeutics earnings, with estimates ranging from ($0.42) to ($0.32). Aquestive Therapeutics posted earnings per share of ($0.60) during the same quarter last year, which []

Aquestive Therapeutics, Inc. (NASDAQ:AQST) saw a large increase in short interest in October. As of October 29th, there was short interest totalling 1,480,000 shares, an increase of 22.3% from the October 14th total of 1,210,000 shares. Based on an average trading volume of 495,300 shares, the days-to-cover ratio is currently 3.0 days. Hedge funds have […]

Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q3 2021 Results - Earnings Call Transcript